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Abstract
Background: Overweight and obesity are considered to be serious public health problems. In pediatric populations,
insulin resistance, dyslipidemia, and hypertension associated with obesity occur with increased frequencies. Metformin
is an oral anti-hyperglycemic agent that has been demonstrated to be efficacious in the treatment of diabetic and
non-diabetic obese adults. A considerable amount of pharmacogenetic research has demonstrated that genetic variation
is one of the major factors affecting metformin response. Additionally, potential microbiota-mediated mechanisms of
metformin effect have been recently described. However, scant work has been conducted in children, with no attention
being paid to the potential effects of pubertal development. Thus, the main objective of the present study is to evaluate
the effect of metformin treatment together with lifestyle recommendations in a randomized control trial (RCT) of obese
children according to pubertal stage, genetic variants and signature of gut microbiota.
Methods/design: This is a randomized, prospective, double-blind, placebo-controlled, multicenter trial, which is stratified
by puberty and sex. Eighty pre-pubertal (40 boys and 40 girls) and 80 pubertal non-diabetic obese children (40 boys and
40 girls) are being recruited in four Spanish Clinical Hospitals. The inclusion criteria to participate in the RCT include a
Body Mass Index (BMI) above the 95th percentile and age 7–14 years. The pubertal stage is determined based on the
Tanner criteria. Participants are assigned to two groups in accordance with a randomization schedule and receive 1 g of
metformin or placebo for six months in combination with healthy lifestyle recommendations in both groups. The primary
outcomes include changes in the BMI Z score and the biomarkers associated with the early appearance of insulin
resistance syndrome, inflammation, cardiovascular risk according of the presence of genetic determinants of metformin
response, as well as possible modifications in microbiota.
Discussion: This study will assess the differential response of metformin treatment at six months in pre-pubertal and
pubertal obese children.
Trial registration: Registered by European Clinical Trials Database (EudraCT, ID: 2010-023061-21) on 14 November 2011.
Keywords: Metformin, Children, Obesity, Puberty, Lifestyle intervention, Microbiota, Polymorphisms
* Correspondence: caguiler@ugr.es
1Department of Biochemistry and Molecular Biology II, Institute of Nutrition
and Food Technology, Center of Biomedical Research Laboratory 123,
University of Granada, Avenida del Conocimiento s/n. 18006 Armilla,
Granada, Spain
9CIBER Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Madrid,
Spain
Full list of author information is available at the end of the article
© 2016 Pastor-Villaescusa et al. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pastor-Villaescusa et al. Trials  (2016) 17:323 
DOI 10.1186/s13063-016-1403-4
Background
The increased prevalence of obesity in pediatric popula-
tions is a public health problem [1]. Insulin resistance,
impaired glucose tolerance, dyslipidemia, and hyperten-
sion are increased in children [2–4]. These metabolic
alterations, which primarily result from obesity, begin in
childhood and may manifest during adolescence or
young adulthood, with diet and a sedentary lifestyle
playing decisive roles [5]. In addition to a lifestyle inter-
vention program, pharmacological treatments have been
explored. Several drugs have been approved by the Food
and Drug Administration (FDA) for the treatment of
adult obesity. Currently, orlistat and sibutramine remain
widely used in clinical practice in adults. Only orlistat
has been approved for use in adolescents [6].
Metformin is an oral anti-hyperglycemic agent approved
by the FDA to treat type 2 diabetes (T2D) in adults and
children older than 10 years of age. Significant weight loss
induced by metformin treatment has been demonstrated
in both diabetic and non-diabetic obese adult patients [7].
In contrast, there is insufficient evidence regarding the
effects of metformin in pediatric obesity. Several clinical
trials have identified modest improvements following
metformin treatment in insulin sensitivity in obese chil-
dren with normal glucose tolerance [8–10], as well as a
decrease in the BMI of obese adolescents [11]. In addition,
metformin appears to improve lipid profiles in obese
children [12, 13]. However, little is known regarding the
effects of metformin, along with diet and exercise, on
other measures associated with cardiovascular risk and
inflammatory biomarkers. Six studies have evaluated the
effects of doses of between 1000 and 2000 mg/day for
3–36 months in obese children and/or adolescents on
inflammatory biomarkers related to obesity [10, 14–18].
These studies identified promising results, but did not
follow a homogeneous distribution according to pubertal
stage. Puberty is a very relevant confounding factor with a
potential influence on insulin resistance development.
Thus, randomized control trials (RCTs) with adequate
statistical power appear necessary to enable the examin-
ation of these potential confounders [19], apart from a
methodology based on a completely homogeneous distri-
bution of factors, such as puberty and sex.
Furthermore, the composition of gut microbiota
during early life has been proposed to influence the
development of obesity and metabolic disease in chil-
dren [20]. The scientific community emphasizes the
need to disentangle gut microbiota signatures of specific
human diseases from medication treatment success.
Interestingly, the microbial mediation of the thera-
peutic effects of metformin through short-chain fatty
acid production, as well as the potential microbiota-
mediated mechanisms behind known intestinal ad-
verse effects in the form of a relative increase in the
abundance of Escherichia species have been demon-
strated [21].
On the other hand, studies have shown variability in
the therapeutic response of metformin treatment in T2D
or obese patients. Variations in metformin response may
reflect phenotypic differences in drug action or drug
distribution. Genetic polymorphisms in drug uptake
transporter genes have been increasingly recognized as a
possible mechanism accounting for variation in drug
response [22–24]. Therefore, the inclusion of genetic
analyses in RCTs could be determinant to elucidate the
variations in metformin response.
Methods
Objectives
In accordance with the previously discussed background,
the present study has four main objectives: the first
objective is to determine the efficacy of metformin in
combination with a lifestyle intervention in reducing
BMI in obese children compared with placebo after
6 months; the second objective is to evaluate the effects
on insulin resistance inherent to metabolic syndrome;
the third objective is to identify its effects on inflamma-
tory, cardiovascular risk and oxidative stress biomarkers;
the fourth objective is to evaluate the change of gut micro-
biota composition after treatment. Additionally, metfor-
min differential response will be analyzed according to
genetic polymorphisms in drug uptake transporter genes.
Study design
The study is a multicenter investigation, stratified by sex
and puberty (40 pre-pubertal girls, 40 pre-pubertal boys,
40 pubertal girls, and 40 pubertal boys). The patient dis-
tribution among groups is indicated in Fig. 1. The puber-
tal stage is determined based on the Tanner criteria [25].
This randomized, prospective, double-blind, placebo-
controlled, multicenter trial is being conducted at four
Spanish Hospitals: Córdoba, Granada, Santiago de Com-
postela and Zaragoza (Table 1).
Children are randomly assigned to receive metformin
or placebo for six months. Both treatments are adminis-
tered during meals (to minimize gastrointestinal side
effects and the risk of hypoglycemia). The participants’
parents are given a coded vial of pills that contains
either metformin or placebo pills for two months. The
concealed allocation process ensures that the partici-
pants and all investigators are unaware of the allocated
treatment. All participants are offered lifestyle interven-
tion advice at all visits.
The clinical hospitals that participate in the RCT form
part of the Maternal and Child Health and Development
(SAMID network). Moreover, the RCT has been
registered in the European Clinical Trials Database on
14 November 2011 (EudraCT, ID: 2010-023061-21).
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In accordance with the “International Conference on
Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use” Guide (ICH): “CPMP/
ICH/291/96 Note for Guidance on General Considerations
for Clinical Trials,” this is a phase III clinical trial because
it involves a commercialized drug for which a new indica-
tion that is not included in its technical specifications will
be investigated.
The CONSORT statement (Consolidated Standards of
Reporting Trials) has been taken into account in the
study design report, as well as for the abstract and the
flow diagram (Fig. 1), thereby increasing the reporting
quality for the RCT. Moreover, the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) guidelines for this study protocol are attached
in Additional file 1.
Assessed for eligibility
Randomized (n= 160)
40 PPG, 40 PPB, 40 PG, 40 PB
Allocated to placebo intervention (n=80)
Allocation
Enrollment
Allocated to metformin intervention (n=80)
Lost to follow-up (n=?)
Analyzed (n=?)
Excluded for analysis (n=?)
Completed trial (n=?)
Follow-Up
(6 months) Lost to follow-up (n=?)
Analyzed (n=?)
Excluded for analysis (n=?)
Fig. 1 Participant flow diagram. PPG pre-pubertal girls; PPB pre-pubertal boys; PG pubertal girls; PB pubertal boys
Table 1 Distribution of patients according to center
Hospital Total (160)
Reina Sofía (Córdoba) 20 pre-pubertal girls
20 pre-pubertal boys








Lozano Blesa (Zaragoza) 20 pubertal girls
20 pubertal boys
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Participants
The study subjects comprise patients referred from the
Pediatric Endocrinology Unit of the corresponding study
centers. Children are eligible for this RCT if they meet
the inclusion criteria (Table 2). The data are collected in
the pediatric outpatient clinics by dieticians. The data and
samples are codified according to each center and subse-
quently centralized at the Institute of Nutrition and Food
Technology “José Mataix” (INYTA) in Granada, Spain.
Randomization
The participants are assigned to metformin or placebo
in accordance with a randomization schedule generated
by the Pharmacy Service of the Virgen de las Nieves
University Hospital in Granada, with MAS 100 version
2.1 software (Glaxo-Welcome, Madrid, Spain) by the
Support Consortium to Biomedical Research Network
(CAIBER). At each center, 50 % of the children are
assigned to each group.
The drug presentation format for the metformin and
placebo groups has the same appearance. The local
physician responsible for the procedure is only aware of
the box/bottle codes of the tablets (as well as the regis-
tration number of the participating child). These codes
have a corresponding equivalent available only to the
coordinating investigator who has the other data of
pharmaceutical interest, such as the origin, lot number
and manufacturing and packaging dates (as well as
whether the drug is metformin or placebo). The afore-
mentioned local physician is not aware of these data and
thus assigns the participant to one study group, without
knowledge of the primary treatment administered.
Breaking of the study blind
All research staff are blinded for both the treatment
allocation during the time of the study and the data
analysis. The study blind will be broken after all analyses
are completed. In the case of emergencies (e.g., serious
adverse events, potentially unexpected serious adverse re-
actions), the blind will be broken following consultation
with the principal investigator. These events will subse-
quently be reported to the Medical Ethics Committee.
Interventions
The patients are instructed to taking a initial dose of
50 mg twice daily for 10 days, followed by 500 mg twice
daily until the end of the treatment. The presentation
comprises tablets in opaque, white plastic containers and
a side label with 28 units. The dietician centers administer
a food frequency questionnaire (FFQ) and a physical activ-
ity survey to all participants at the beginning and at the
end of the trial. All participants are provided with stan-
dardized healthy lifestyle advice at the start of a one-on-
one session, including a healthy diet and exercise advice
sheet. The participants attend an initial trial baseline visit,
followed by three additional visits at 2-month intervals
(Fig. 2), which include anthropometric parameter and
blood pressure (BP) assessments, as well as a physical
examination. A medical history is obtained for each
participant, including documentation of the family
history.
To ensure the traceability of the treatments, a system-
atic record of the name of the pharmaceutical preparation,
and the quantity and lot number dispensed to each subject
are maintained in the corresponding data collection book.
The data are updated according to the standard working
procedures (SWPs) for the preparation and control of
500-mg metformin tablets and according to the SWPs for
the control of pills, which are provided by the Hospital
Pharmacy Department.
At the first visit, an extensive history is obtained. The
duration of pregnancy, birth weight, neonatal feeding, use
of medication, tobacco and alcohol, and the presence of
maternal gestational diabetes are reported. Regarding
family history, data on hypertension, obesity, hypercholes-
terolemia, cardiovascular disease, and diabetes mellitus in
first-degree (parents) and second-degree (grandparents)
family members are collected. Girls are asked whether and
when they experienced menarche. The parental education
level is recorded, as well as height and weight.
Adverse effects and co-medication
To assess the safety of metformin administration, the
primary evaluation criteria are the absence of the adverse
effects (AEs) described. The patients are assessed regard-
ing all symptoms at each visit to identify potential AEs
and the use of co-medication in the previous two months.
A contact number is provided to enable enquiries regard-
ing any symptom perceived as adverse. At this number,
the patient is informed about what to do in the event of
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
BMI greater than the 95th percentile
based on the standards set by
Cole et al. [26]
Does not meet the established
age
Age 7–14 years Any previous underlying disease
No underlying disease or a history
of pathology
Use of medication with
metabolic side effects, such as
diuretics, β-blockers, β-
adrenergics, or corticoids
No medical treatment regarding
weight control in the previous
12 months
Cases of monogenic obesity
No participation in a previous trial Children subjected to long
periods of rest
Did not sign the informed
consent
BMI Body Mass Index
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an adverse reaction. They are also requested to suspend
the medication. The following information is recorded:
description, date of onset and end date, severity, assess-
ment of relation to the study medication, other suspect
drug or device and action taken. Follow-up information
should be provided as necessary. The prominent AEs are
as follow: diarrhea, nausea, blood in the stools, headache,
dizziness, general discomfort, sleepiness, cold or flu, pha-
ryngitis, otitis, allergic episode, lactic acidosis, urea incre-
ment, hypercreatininemia, hypertransaminasemia and
vitamin B12 deficiency, as well as any other symptoms re-
ported by the participants. The relationships of the
AEs to the study medication will be assessed by a quali-
fied medical investigator.
Physical examination
The Clinical Units conduct a complete medical examin-
ation, which is performed with pubertal assessment.
Measurements of arterial BP, calibrated by hand and in
duplicate, and heart rate are obtained with the subjects
in a seated position using a cuff appropriate for the arm
circumference. The average BP values are expressed in
mmHg, and the percentiles are determined and adjusted
for sex and age according to the chart published by the
National Heart, Lung and Blood Institute.
At every visit, an extended physical examination is
performed by the research physician. This examination
includes auscultation of the heart, lungs and abdomen
and also abdominal palpation. Clinical signs may be iden-
tified, including the presence of acanthosis nigricans,
hypertrichosis, striae, acne, adipomastia or hypogonadism.
Monitoring of lifestyle
The dietician centers administer a FFQ and a physical ac-
tivity survey to all participants at the beginning and at the
end of the trial. Both questionnaires have been normalized
by the IDEFICS and HELENA European Projects [26] and
validated by the CTS-02203 Excellence Project of the Re-
gional Government of Andalucía. The HELENA Study de-
veloped and tested a questionnaire for use among
adolescents, based on the long format of the Inter-
national Physical Activity Questionnaire (IPAQ) [27],
which provided internationally comparable data [28].
Blood, urine and fecal sampling
General biochemical analyses are performed at the
participating hospitals following internationally accepted
protocols.
Blood samples are obtained for biochemical and
hematological screening tests between 08.30 and 10.30.
Fig. 2 Activity schedule that may occur during each contact with the participant
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Three milliliters of blood are collected at the beginning
and at the end of the trial. The blood is drawn via the
antecubital vein. Peripheral white blood cells (buffy coat)
are taken for deoxyribonucleic acid (DNA) extraction.
Moreover, a 1-ml urine sample is obtained for oxidation
marker analysis. Children should not eat for 12 hours
before the sampling. All samples are collected and stored
frozen by the research staff. The samples will be
analyzed in the clinical laboratory of each hospital, as
well as the INYTA.
In order to studying the childrens’ gut microbiota,
100–200 g of fecal sample is collected in a sterile
container by parents at the beginning and at the end of
the trial. Immediately, all samples are stored frozen until
to be analyzed at the INYTA.
Adherence and tolerance




These data will also be taken into account for statistical
analysis as fixed effects. Tolerance is reported as the
descriptive statistics of the adverse effects in relation to
the achieved dosage level.
Sample size
As previously indicated, the principal variable is the BMI
Z score, on which the sample size calculation was based.
Its standard deviation is 2.29 in the least favorable case
(according to the tables by Cole et al. [29]), and a de-
sired minimum difference of 2 points is expected. With
an α error of 0.05, a β error of 0.20 and an estimated
follow-up loss of 20 %, four groups in total are planned
for the study: two groups of obese children (pre-pubertal
and pubertal) treated with metformin and two groups of
obese children (pre-pubertal and pubertal) treated with a
placebo; there is a requirement of at least 40 patients
per group (× four groups = 160 children total).
The clinical argument for the choice of the principal
variable adheres to the fact that the obesity concept is
based on the BMI, as the bibliography endorses. However,
it should be noted that the BMI in childhood changes sub-
stantially with age [30]. Thus, age- and sex-specific cut-off
points are needed to define pathology in children via
means of a Z score [29] to obtain a more accurate value.
Statistical analysis
Data will be analyzed using SPSS software version 22 for
Windows. Descriptive statistics for all outcomes will be
determined. A Kolmogorov-Smirnov test will be used to
test data normality. Data that are not normally
distributed will be transformed by means of a log10 or
square root for analysis. The homogeneity of variances
will be determined with a Levene’s test. Normally dis-
tributed data will be reported as mean ± standard devi-
ation (SD) and nonparametric data as median (range).
The analysis selected to determine the effect of treat-
ment is a linear mixed effects model (LMM), for which
the center is considered covariance to adjust the statis-
tical analysis. The fixed effects include time, treatment,
adherence, puberty, sex, the interactions time × treat-
ment, time × treatment × puberty and time × treatment ×
sex. A Bonferroni test will be used to assess the specific
differences between the treatments.
Regarding genetic variations, linear regression will be
performed to analyze differences in principal variable
changes between genotypes and to evaluate independent
associated factors.
Moreover, the raw microbiologic data are reported as
relative abundances. Differences among times, treatments
and puberty are compared using the Mann-Whitney U test.
Finally, the clustering of the colonic microbiota in both of
groups is calculated by a principal component analysis.
Interim analyses and stopping rules
Interim or preliminary analyses during the course of this
RCT are not planned. In the event of subject withdrawal, a
replacement or substitution is not planned; thus, these par-
ticipants will be considered lost. The data associated with
these subjects will subsequently be excluded from the stat-
istical analysis. For this reason, the calculation of the sample
size has included a potential loss of up to 20 %.
Outcome measures
Anthropometry
Body weight (kg), height (cm) and waist circumference
(cm) are measured via standardized procedures. The BMI
and BMI Z score are calculated based on Spanish refer-
ence standards published by Sobradillo et al. [31]. Obesity
is defined according to the BMI, with the age and sex-
specific cut-off points proposed by Cole et al. [29] (BMI
>95th percentile). Anthropometric measurements are ob-
tained by a single examiner with the children barefoot and
in their underwear. To obtain data on body composition,
fat mass, lean mass and total body water are measured via
bioimpedance technology using Tanita B18.
Biochemical analysis
The serum concentrations of glucose, lipids (total
cholesterol, triglycerides (TG), high-density lipoprotein
cholesterol (HDLc), and low-density lipoprotein choles-
terol (LDLc)), apolipoprotein A1 (Apo-A1) and apolipo-
protein B (Apo-B) are analyzed via spectrophotometry
or a chemiluminescent microparticle immunoassay
(CMIA) to measure the insulin concentration, according
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to auto-analyzers with standardized methods and both
intra- and inter-laboratory control using internal and
external quality control programmers at the Clinical
Analysis Laboratory of each hospital. The Quantitative
Insulin Sensitivity Check Index (QUICKI) and the
homeostasis model assessment for insulin resistance
(HOMA-IR) are calculated using the fasting plasma
glucose and insulin values:
HOMA ¼ Fasting insulin ðμU=mlÞ
fasting glucose ðmmol=lÞ=22:51=
ðLog fasting insulin ðμU=mlÞ
þlog fasting glucose ðmg=dlÞÞ
Inflammation and cardiovascular risk biomarkers
Specific biomarkers of inflammation and cardiovascular
risk, including adiponectin, leptin, resistin, myeloperoxi-
dase (MPO), plasminogen activator inhibitor-1 (PAI-1),
tumor necrosis factor-alpha (TNF-α), monocyte chemo-
attractant protein-1 (MCP-1), interleukin-6 (IL-6),
interleukin-8 (IL-8), soluble intercellular adhesion
molecule-1 (sICAM-1), soluble endothelial selectin (sE-
Selectin) and soluble vascular adhesion molecule-1
(sVCAM-1) are analyzed in duplicate on a Luminex 200
system with the XMap technology (Luminex Corporation,
Austin, TX, USA) and using human monoclonal anti-
bodies (Milliplex Map Kit, Millipore, Billerica, MA, USA).
Oxidation biomarkers
The plasma total antioxidant capacity (TAC) is assessed
with a spectrophotometric commercial antioxidant assay
kit (Cayman, Ann Arbor, MI, USA), which is based on a
colorimetric reaction. The oxidized LDL (Cayman, Ann
Arbor, MI, USA), as well as the oxidative stress
biomarkers isoprostane (Oxford Biomedical Research,
Oxford, UK) and 8-hydroxy-2-deoxyguanosine (JaICA
(Japan Institute for the Control of Ageing), Fukuroi,
Shizuoka, Japan) are determined in duplicate via
enzyme-linked immunosorbent assay (ELISA) in urine
using a microplate reader BioTeK synergy HT.
Microbiota analysis
The fecal samples are subjected to extracting and purifying
microbial DNA by a specific commercial DNA kit for
purification (QIAamp DNA Stool Mini Kit, Quiagen,
Barcelona, Spain). Quantification is conducted with a
NanoDrop ND-1000 spectrophotometer (Thermo Fisher
Scientific, Newark, DE, USA) in the Department of Micro-
biology, University Hospital San Cecilio (Granada, Spain).
Polymerase chain reaction (PCR) is performed in a
FastStart High Fidelity PCR System, dNTP Pack (Roche
Applied Science). After PCR, amplicons are further
purified using AMPure XP beads (Beckman-Coulter) to
remove smaller fragments. DNA concentration and quality
are measured using a Quant-iT™ PicoGreen® dsDNA Assay
Kit. Afterwards, pyrosequencing of the PCR amplicons is
performed using a Roche/454 GS Titanium technology
platform (Roche, Branford, CT, USA). The MG-RAST
(metagenomics analysis server) and the Ribosomal Data-
base Project are used for the taxonomic analysis. Metage-
nomics data will be deposited in the publicly available
repository MG-RAST (http://metagenomics.anl.gov/).
DNA isolation and genotyping
Genomic DNA is extracted from peripheral white blood
cells (buffy coat) using the Zymo ZR-96 Quick-gDNA
kit (Zymo Research Corporation, Irvine, CA, USA) ac-
cording to the manufacturer’s instructions. Eleven single
nucleotide polymorphisms (SNPs) previously described
as being involved in the success of metformin treatment
are being selected along several genes: the ataxia
telangiectasia mutated (ATM, rs11212617); the glucoki-
nase regulatory protein (GCKR, rs1260326); the serine-
threonine kinase 11 (STK11, rs8111699); the peroxisome
proliferator-activated receptor gamma, coactivator 1 alpha
(PPARGC1A, rs2970852); the insulin-induced gene 2
(INSIG2, rs7566605); the neuronal growth regulator 1
(NEGR1, rs2815752); the solute carrier family 22 (organic
cation transporter), member 1 (SLC22A1, rs622342); the
solute carrier family 47 (multidrug and toxin extrusion),
member 1 (SLC47A1, rs2289669); the transmembrane
protein 18 (TMEM18, rs6548238), the potassium channel
tetramerization domain containing 15 (KCTD15,
rs29941); and the fat mass- and obesity-associated protein
(FTO, rs9939609). Genotyping will be performed in dupli-
cate using TaqMan® OpenArray® Genotyping Plates (Ther-
moFisher Scientific, Madrid, Spain).
Discussion
The studies of the efficacy of metformin treatment in
obese children and adolescents have been small, of short
duration, or have used nonstandard doses of metformin
and have produced inconclusive results. McDonagh et
al. [19] examined the literature regarding obese children
via a systematic review and meta-analysis and indicated
the need for investigations of the effects of metformin
treatment that consider the influence of potential con-
founding factors, such as puberty and sex. Similarly, tri-
als with adequate statistical power that enable an
examination of these potential confounders are
mandatory. Nine trials mention the pubertal stage in
their publications [8, 10, 11, 14, 16, 18, 32–34]. Although
puberty has been considered in the study design by a
limited number of authors, none of these authors used a
homogenized sample division. Wilson et al. and
Wiegand et al. predominantly recruited children who
were further advanced in puberty [11, 33]. Yanovski et
al. only considered pre-pubertal children or children in
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early puberty (Tanner I–III) [34], whereas Burgert et al.
and Evia-Viscarra et al. only included adolescent
volunteers [10, 14] and Freemark et al. included those at
Tanner III [32]. Furthermore, the sample size has also
been an important element: Srinivasan et al. recognized
that the patient numbers were insufficient to statistically
assess the effect of pubertal stage on the response to
metformin therapy (n = 28, 14 pre-pubertal; 14 pubertal)
[8]. Mauras et al. [16] evaluated metformin treatment
with individual lifestyle coaching in pre- and pubertal
children compared with a control group for six months.
However, differences between the puberty groups based
on metformin treatment were not identified. Furthermore,
Kendall et al. [18] also examined the effects of metformin
on obese children for six months. They did not identify a
differential response to metformin according to the
pubertal stage when they used a multifactorial regression
analysis. This finding may also be explained by the
small number of valid cases in the analysis segmented
by puberty.
Additionally, during the last years the importance has
been demonstrated of determining the specific contribu-
tion of the human gut microbiome to the pathogenesis
of obesity to allow for the development of effective treat-
ment strategies. Recently, an elegant study by Forslund
et al. published in Nature identifies specific disease and
drug signatures in the human gut microbiome of T2D
patients treated with metformin [21]. By analyzing the
dataset without stratifying for treatment regimens, they
replicated the majority of previously reported results and
showed a large divergence between the study popula-
tions. However, composition of gut microbiota from
children treated with metformin has not been studied.
Taking into account the proven role of the microbiota
on childhood obesity development [20], the development
of RCTs adjusting the effects according to the human
gut microbiome is necessary.
Finally, a considerable amount of pharmacogenetic
research has demonstrated that genetic variation is one
of the major factors affecting metformin response [35].
Moreover, it has become increasingly clear that the
pharmacokinetics of metformin are primarily deter-
mined by membrane transporters, including the plasma
membrane monoamine transporter, the organic cation
transporters (OCTs), the multidrug and toxin extrusion-1
transporter (MATE1), and the critical AMPK. In this
RCT, we will analyze the genetic variants previously
proved to determine the pharmacokinetics of metformin
[36] and a differential response after treatment in obese
subjects. Genes included are related to metformin
transporters (SLC22A1 and SLC47A1), AMPK and the
gluconeogenesis pathway (ATM, STK11 and PPARGC1A),
insulin sensitivity (GCKR and INSIG2) and weight loss or
weight regain predictors (FTO, TMEM18, NEGR1 and
KTCD15) Understanding how genetic variation affects
metformin response will help to promote more effective
use of the drug for the treatment of childhood obesity.
In view of this situation, our research could provide
consolidated evidence regarding metformin’s effects on
obese children, considering the pubertal stage via homo-
geneous Tanner stratification, as well as finding possible
lines of action by metformin. Nevertheless, the study has
several limitations, including the difficulty of assessing
treatment compliance in children, as well as lifestyle
changes. Moreover, the supervision of dietary habits and
physical activity proves rather complicated. We are con-
trolling for medication taken by means of the delivery
and return of the bottles; however, we are aware that this
strategy does not ensure accuracy regarding intervention
compliance information.
Trial status
Currently, the trial is ongoing and recruitment of partici-
pants continues.
Additional file
Additional file 1: SPIRIT 2013 Checklist (17.05.2016). File outlining how
this study protocol meets the different guidelines from the SPIRIT 2013
Checklist. (PDF 48 kb)
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Insulin Sensitivity Check Index; RCT, randomized clinical trial; sE-Selectin, soluble
endothelial selectin; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1,
soluble vascular adhesion molecule-1; T2D, type 2 diabetes; TAC, total antioxidant
capacity; TNF-α, tumor necrosis factor-alpha; TMEM18, transmembrane protein 18
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